As of November 10, 2026, Immunocore Holdings plc is a publicly traded company (Nasdaq: IMCR); its largest reported holder is Wellington Management, with 11.6% on Schedule 13G/A of August 13, 2026, then Bellevue Group AG (5.6%) (Schedule 13G/A, August 13, 2026).
Is this your company?
About to sign with, pay or invest in Immunocore Holdings plc? See the free Snapshot first.
Free to see. No signup.
Is Immunocore Holdings plc a real, registered company?
- Immunocore Holdings plc files with the SEC under CIK 1671927 (its SEC filings).
- Its shares are listed under the ticker IMCR on Nasdaq (SEC company record).
- Incorporated in X0; business address in Oxfordshire, X0, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Immunocore Holdings plc in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Point72 (filed 2026-11-09).
Who are Immunocore Holdings plc's owners and officers?
Immunocore Holdings plc: business address in Oxfordshire, X0; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-09 | Point72 Asset Management, L.P. | 5.2% |
| Schedule 13G/A, 2026-10-07 | Fmr LLC | 3.6% |
| Schedule 13G/A, 2026-08-14 | Vestal Point Capital, LP | 3.5% |
| Schedule 13G/A, 2026-08-13 | Wellington Management Group LLP | 11.6% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.8% |
| Schedule 13G, 2026-05-15 | Vestal Point Capital, LP | 5.5% |
| Schedule 13G/A, 2026-05-15 | T. Rowe Price Investment Management, Inc. | 3.7% |
| Schedule 13G/A, 2026-03-06 | T. Rowe Price Investment Management, Inc. | 6% |
| Schedule 13G/A, 2026-02-17 | T. Rowe Price Investment Management, Inc. | 11.8% |
| Schedule 13G, 2025-11-14 | Bellevue Group Ag | 5.6% |
| Schedule 13G, 2025-10-24 | Tang Capital Management, LLC | 5.2% |
| Schedule 13G/A, 2025-10-03 | Eli Lilly & Co | 0% |
Questions about who owns Immunocore Holdings plc
Who owns Immunocore Holdings plc?
On this page, 4 holders' latest ownership filings report 5% or more of Immunocore Holdings plc: Wellington Management Group LLP (11.6%, Schedule 13G/A, filed 2026-08-13), Bellevue Group Ag (5.6%, Schedule 13G, filed 2025-11-14), Point72 Asset Management, L.P. (5.2%, Schedule 13G, filed 2026-11-09) and Tang Capital Management, LLC (5.2%, Schedule 13G, filed 2025-10-24).
Who are the largest shareholders of Immunocore Holdings plc?
By the share each holder's latest filing reports, the largest holders of Immunocore Holdings plc on this page are Wellington Management Group LLP (11.6%), Bellevue Group Ag (5.6%) and Point72 Asset Management, L.P. (5.2%).
When did Wellington Management Group LLP buy into Immunocore Holdings plc?
The filings give report dates, not purchase dates. The earliest filing from Wellington Management Group LLP on this page is the Schedule 13G/A, filed 2026-08-13, reporting 11.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Immunocore Holdings plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Immunocore Holdings plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunocore Holdings plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Immunocore Holdings plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- 667, L.P., a director: 2,144,060 shares (4.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-03-19).
- , a director: 2,144,060 shares (4.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-03-19).
- Baker Bros. Advisors (GP) LLC, a director: 2,144,060 shares (4.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-03-19).
- Baker Brothers Life Sciences LP, a director: 2,144,060 shares (4.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-03-19).
- , a director: 2,144,060 shares (4.1% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-03-19).
Shares outstanding: 51,681,376 as of 2026-10-31, from the company's latest SEC cover page.
How much has Immunocore Holdings plc raised?
No fundraising or offering filing from Immunocore Holdings plc is on file with us.
Keep reading
More on Immunocore Holdings plc and the records around it.
Immunocore Holdings plc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- ELI LILLY & Co also filed stake reports on 5 other companies: TRex Bio, Inc. (Oct 2026), Scribe Therapeutics, Inc. (Jul 2026), Ionetix Corp / DE / (Jul 2026)
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Jade Biosciences, Inc. (Aug 2026), Celldex Therapeutics, Inc. (May 2026)
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/immunocore